BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 32487052)

  • 1. Predictors of euthyreosis in hyperthyroid patients treated with radioiodine
    Stachura A; Gryn T; Kałuża B; Budlewski T; Franek E
    BMC Endocr Disord; 2020 Jun; 20(1):77. PubMed ID: 32487052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioiodine treatment of hyperthyroidism: prognostic factors affecting outcome.
    Erem C; Kandemir N; Hacihasanoglu A; Ersöz HO; Ukinc K; Kocak M
    Endocrine; 2004 Oct; 25(1):55-60. PubMed ID: 15545707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of radioiodine (131-I) as definitive therapy in patients with autoimmune and non-autoimmune hyperthyroidism.
    Tarantini B; Ciuoli C; Di Cairano G; Guarino E; Mazzucato P; Montanaro A; Burroni L; Vattimo AG; Pacini F
    J Endocrinol Invest; 2006; 29(7):594-8. PubMed ID: 16957406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Administration of a single dose of recombinant human thyrotrophin enhances the efficacy of radioiodine treatment of large compressive multinodular goitres.
    Silva MN; Rubió IG; Romão R; Gebrin EM; Buchpiguel C; Tomimori E; Camargo R; Cardia MS; Medeiros-Neto G
    Clin Endocrinol (Oxf); 2004 Mar; 60(3):300-8. PubMed ID: 15008994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term Effects of Radioiodine in Toxic Multinodular Goiter: Thyroid Volume, Function, and Autoimmunity.
    Roque C; Santos FS; Pilli T; Dalmazio G; Castagna MG; Pacini F
    J Clin Endocrinol Metab; 2020 Jul; 105(7):. PubMed ID: 32320467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of a dosimetry-based RAI protocol for treatment of benign hyperthyroidism optimises response while minimising exposure to ionising radiation.
    Miller C; Al-Jabri A; O'Murchada L; Mustafa M; Cooke J; Phelan N; Healy ML
    Clin Endocrinol (Oxf); 2024 Jun; 100(6):585-592. PubMed ID: 38567706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Radioiodine treatment of hyperthyroidism using a simplified dosimetric approach. Clinical results].
    Giovanella L; De Palma D; Ceriani L; Vanoli P; Garancini S; Tordiglione M; Tarolo GL
    Radiol Med; 2000 Dec; 100(6):480-3. PubMed ID: 11307510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ultrasonography thyroid volume estimation in hyperthyroid patients treated with individual radioiodine dose.
    Massaro F; Vera L; Schiavo M; Lagasio C; Caputo M; Bagnasco M; Minuto F; Giusti M
    J Endocrinol Invest; 2007 Apr; 30(4):318-22. PubMed ID: 17556869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of hyperthyroidism caused by Graves' disease or toxic multinodular goitre by radioiodine: over 80% cure retrospectively after one calculated dose].
    Bakker SC; Zanin DE; Zweers EJ
    Ned Tijdschr Geneeskd; 2002 Sep; 146(39):1837-41. PubMed ID: 12382370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioiodine therapy in hyperthyroidism: inverse correlation of pretherapeutic iodine uptake level and post-therapeutic outcome.
    Walter MA; Christ-Crain M; Eckard B; Schindler C; Nitzsche EU; Müller-Brand J; Müller B
    Eur J Clin Invest; 2004 May; 34(5):365-70. PubMed ID: 15147334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High prevalence of side effects after recombinant human thyrotropin-stimulated radioiodine treatment with 30 mCi in patients with multinodular goiter and subclinical/clinical hyperthyroidism.
    Romão R; Rubio IG; Tomimori EK; Camargo RY; Knobel M; Medeiros-Neto G
    Thyroid; 2009 Sep; 19(9):945-51. PubMed ID: 19678745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism.
    Franklyn JA; Daykin J; Holder R; Sheppard MC
    QJM; 1995 Mar; 88(3):175-80. PubMed ID: 7767667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioactive iodine therapy for pediatric Graves' disease: a single-center experience over a 10-year period.
    Kaplowitz PB; Jiang J; Vaidyanathan P
    J Pediatr Endocrinol Metab; 2020 Mar; 33(3):383-389. PubMed ID: 31603857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up study of radioiodine treatment of hyperthyroidism.
    Metso S; Jaatinen P; Huhtala H; Luukkaala T; Oksala H; Salmi J
    Clin Endocrinol (Oxf); 2004 Nov; 61(5):641-8. PubMed ID: 15521969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of radioiodine therapy in hyperthyroidism (thyroid function, thyroid volume, Graves' ophtalmopathy, thyrotoxic heart disease).
    Ursu HI; Dumitriu L; Grigorie D; Simescu M; Vaida E; Belgun M; Popovici D
    Rom J Endocrinol; 1993; 31(3-4):155-63. PubMed ID: 7697064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioiodine treatment of hyperthyroidism in patients with low thyroid uptake.
    Ruchała M; Sowiński J; Dolata M; Junik R; Gembicki M; Skiba A
    Nucl Med Rev Cent East Eur; 2005; 8(1):28-32. PubMed ID: 15977144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective pituitary resistance to thyroid hormone after treatment of a toxic multinodular goiter.
    Vesely DL
    South Med J; 1988 Sep; 81(9):1173-6. PubMed ID: 3420449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of stimulating thyrotropin receptor antibodies after radioiodine therapy for toxic multinodular goitre and Graves' disease measured with a novel bioassay.
    Hovens GC; Heemstra KA; Buiting AM; Stokkel MP; Karperien M; Ballieux BE; Pereira AM; Romijn JA; Smit JW
    Nucl Med Commun; 2007 Feb; 28(2):123-7. PubMed ID: 17198353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage.
    Chiovato L; Fiore E; Vitti P; Rocchi R; Rago T; Dokic D; Latrofa F; Mammoli C; Lippi F; Ceccarelli C; Pinchera A
    J Clin Endocrinol Metab; 1998 Jan; 83(1):40-6. PubMed ID: 9435414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Impact of pretreatment variables on the outcome of standardized 131I therapy with 150 Gray in Graves' disease].
    Pfeilschifter J; Elser H; Haufe S; Ziegler R; Georgi P
    Nuklearmedizin; 1997 Apr; 36(3):81-6. PubMed ID: 9162906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.